# EDGAR Filing Document

**Accession Number:** 0000885590
**File Stem:** 0000885590-26-000057
**Filing Date:** 2026-5
**Character Count:** 7078
**Document Hash:** 2b2954679ba765ffbdd41f96e5d5f891
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000885590-26-000057.hdr.sgml**: 20260519

**ACCESSION NUMBER**: 0000885590-26-000057

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 11

**CONFORMED PERIOD OF REPORT**: 20260519

**ITEM INFORMATION**: Submission of Matters to a Vote of Security Holders

**FILED AS OF DATE**: 20260519

**DATE AS OF CHANGE**: 20260519

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Bausch Health Companies Inc.
- **CENTRAL INDEX KEY:** 0000885590
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** NJ
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-14956
- **FILM NUMBER:** 26999001

**BUSINESS ADDRESS:**
- **STREET 1:** 2150 ST. ELZEAR BLVD. WEST
- **STREET 2:** LAVAL
- **CITY:** QUEBEC
- **STATE:** A8
- **ZIP:** H7L 4A8
- **BUSINESS PHONE:** 514-744-6792

**MAIL ADDRESS:**
- **STREET 1:** 2150 ST. ELZEAR BLVD. WEST
- **STREET 2:** LAVAL
- **CITY:** QUEBEC
- **STATE:** A8
- **ZIP:** H7L 4A8

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Valeant Pharmaceuticals International, Inc.
- **DATE OF NAME CHANGE:** 20100928

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** BIOVAIL Corp
- **DATE OF NAME CHANGE:** 20100416

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** BIOVAIL CORP INTERNATIONAL
- **DATE OF NAME CHANGE:** 19960522

?xml version='1.0' encoding='ASCII'? bhc-20260519

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934**

MAY 19, 2026

Date of report (Date of earliest event reported)

**Bausch Health Companies Inc.** 

**(Exact name of registrant as specified in its charter)**

---

| | | | | |
|:---|:---|:---|:---|:---|
| **British Columbia** | **,** | **Canada** | **001-14956** | **98-0448205** |
| (State or other jurisdiction of incorporation) | (State or other jurisdiction of incorporation) | (State or other jurisdiction of incorporation) | (Commission file number) | (IRS Employer Identification No.) |

---

**2150 St. Elzéar Blvd. West, Laval, Québec, Canada H7L 4A8**

(Address of Principal Executive Offices) (Zip Code)

**(514) 744-6792** 

(Registrant's telephone number, including area code)

**N/A**

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | | |
|:---|:---|:---|:---|
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | Name of each exchange on which registered |
| **Common Shares, No Par Value** | **BHC** | **New York Stock Exchange** | **Toronto Stock Exchange** |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company **☐** 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &nbsp;&nbsp;&nbsp;&nbsp;**☐**&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;

------

**Item 5.07. Submission of Matters to a Vote of Security Holders.**

On May 19, 2026, Bausch Health Companies Inc. (the "Company") held its Annual Meeting of Shareholders (the "Annual Meeting"). At the Annual Meeting, the shareholders of the Company voted on the following three proposals, each of which is described in detail in the Company's Management Proxy Circular and Proxy Statement. The results of each matter voted upon are as follows:

**Proposal No. 1: Election of Directors.** The shareholders elected the following individuals to the Company's Board of Directors, including Eiry W. Roberts, M.D., who was elected as a new director, to serve until the close of the Company's 2027 Annual Meeting of Shareholders, until their successors are duly elected or appointed, or until such director's earlier resignation or removal:

---

| | | | |
|:---|:---|:---|:---|
| **Name** | **For** | **Withheld** | **Broker Non-Votes** |
| Thomas J. Appio | 196814621 | 2743810 | 79859606 |
| Christian A. Garcia | 196711908 | 2846523 | 79859606 |
| Michael Goettler | 196757828 | 2800603 | 79859606 |
| Sarah B. Kavanagh | 188459870 | 11098561 | 79859606 |
| Frank D. Lee | 183885617 | 15672814 | 79859606 |
| Sandra Leung | 195931772 | 3626659 | 79859606 |
| John A. Paulson | 196214806 | 3343625 | 79859606 |
| Robert N. Power | 186236066 | 13322365 | 79859606 |
| Eiry W. Roberts, M.D. | 196972752 | 2585679 | 79859606 |
| Amy B. Wechsler, M.D. | 195813955 | 3744476 | 79859606 |

---

**Proposal No. 2: Advisory Vote on Executive Compensation.** The shareholders approved, on a non-binding advisory basis, the compensation of the Company's Named Executive Officers as disclosed in the Compensation Discussion and Analysis section, executive compensation tables and accompanying narrative discussions contained in the Management Proxy Circular and Proxy Statement.

---

| | | | |
|:---|:---|:---|:---|
| **For** | **Against** | **Abstain** | **Broker Non-Votes** |
| 189,432,400 | 9,588,417 | 537,614 | 79,859,605 |

---

**Proposal No. 3: Appointment of the Independent Registered Public Accounting Firm.** The shareholders appointed PricewaterhouseCoopers LLP as the auditors for the Company to hold office until the close of the 2027 Annual Meeting of Shareholders and authorized the Company's Board of Directors to fix the auditors' remuneration.

---

| | |
|:---|:---|
| **For** | **Withheld** |
| 276,774,936 | 2,643,100 |

---

------

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: May 19, 2026

---

| | |
|:---|:---|
| | **BAUSCH HEALTH COMPANIES INC.** |
| By: | */s/ Seana Carson* |
|  | Seana Carson |
|  | Executive Vice President, General Counsel |

---